There are currently the following ongoing research programmes into Barrett’s Oesophagus:
- A collaborative study between UKBOR (UK Barrett's Oesophagus Registry) & Harvard University - further details
- A study to identify Barrett’s Oesophagus susceptibility genes, funded by the Association for International Cancer Research
- A study into blood group distribution in Barrett’s patients
- A study into the causes of mortality in Barrett’s patients
Aspirin & Barrett's Oesophagus
Treatment of Barrett’s Oesophagus using common aspirin is discussed in the European Journal of Cancer.
Please see: Aspirin is not chemoprotective for Barrett's Adenocarcinoma of the oesophagus in multicentre cohort, PA Gatenby, JR Ramus, CP Caygill, MC WInslet, A Watson, European Journal Cancer, Volume 18, no 5 September 09, pp381-4.
New data on Halo RFT
Patients with dysplastic Barrett's Oesophagus who were treated with radiofrequency ablation were more likely to have complete eradication of dysplasia and intestinal metaplasia and less likely to progress to more severe dysplasia or cancer, a study published in New England Journal found.
Currently Radio Frequency Ablation using the HALO System is offered in about seven hospitals in the UK.
You can acquire more information from SynMed Limited. And Radiofrequency Ablation is further discussed in this article in Science Centric.